Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.77 |
| ▸ | MEN1 | O00255 | 5/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 9/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | ESR1 | P03372 | 5/20 | 0.76 |
| ▸ | TP53 | P04637 | 4/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.76 |
| ▸ | PGR | P06401 | 3/20 | 0.76 |
| ▸ | AR | P10275 | 3/20 | 0.76 |
| ▸ | ATM | Q13315 | 3/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8506439 | 1.00 | MAPT (0.77) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL32662764 | 1.00 | MAPT (0.77) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL32662630 | 1.00 | MAPT (0.77) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL31648759 | 1.00 | MAPT (0.77) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL8465006 | 0.99 | MAPT (0.79) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL146888 | 0.96 | LMNA (0.82) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL32661972 | 0.95 | MAPT (0.71) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL9404737 | 0.93 | MAPT (0.83) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL9404738 | 0.91 | LMNA (0.79) | MAPTKMT2AMEN1THRBLMNA | |
| Estradiol Undecylate SCHEMBL453172 | 0.90 | LMNA (0.93) | MAPTKMT2AMEN1THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | claimed |
| EP-4574143-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | Universität Regensburg (DE) | 2025-06-25 | — | — | EP | claimed |
| WO-2023242235-A1 | ABCG2 INHIBITOR AND NAE INHIBITOR FOR THE TREATMENT OF CANCER | SCANDION ONCOLOGY A/S (DK) | 2023-12-21 | — | — | WO | claimed |
| EP-1761252-A1 | MATRIX-CONTROLLED TRANSDERMAL THERAPEUTIC SYSTEM BASED ON AN ADHESIVE FOR ADMINISTERING NORELGESTROMIN OR THE COMBINATION THEREOF WITH AN ESTROGEN | HEXAL AG (DE) | 2007-03-14 | — | — | EP | claimed |
| WO-2005120470-A1 | MATRIX-CONTROLLED TRANSDERMAL THERAPEUTIC SYSTEM BASED ON AN ADHESIVE FOR ADMINISTERING NORELGESTROMIN OR THE COMBINATION THEREOF WITH AN ESTROGEN | HEXAL AG (DE) | 2005-12-22 | — | — | WO | claimed |
| US-12448461-B2 | ABCB5 ligands and substrates | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | disclosed |
| EP-4574143-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | Universität Regensburg (DE) | 2025-06-25 | — | — | EP | disclosed |
| US-20250084398-A1 | SYSTEMS FOR MODULATING DRUG METABOLISM BY CELLS, METHODS AND COMPOSITIONS THEREOF | TROBIX BIO LTD (IL) | 2025-03-13 | — | — | US | disclosed |
| EP-4479034-A1 | CAPSAICIN DERIVATIVES AS BIOENHANCERS ON ACTIVE SUBSTANCES METABOLIZED BY CYP1A2 AND CYP2D6 | aXichem AB (SE) | 2024-12-25 | — | — | EP | disclosed |
| EP-4381061-A1 | SYSTEMS FOR MODULATING DRUG METABOLISM BY CELLS, METHODS AND COMPOSITIONS THEREOF | Trobix Bio Ltd (IL) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023242235-A1 | ABCG2 INHIBITOR AND NAE INHIBITOR FOR THE TREATMENT OF CANCER | SCANDION ONCOLOGY A/S (DK) | 2023-12-21 | — | — | WO | disclosed |
| CN-115835882-A | Targeting ABCB5 in glioblastoma multiforme | 儿童医学中心公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2023012785-A1 | SYSTEMS FOR MODULATING DRUG METABOLISM BY CELLS, METHODS AND COMPOSITIONS THEREOF | TROBIX INNOVATION LTD (IL) | 2023-02-09 | — | — | WO | disclosed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| EP-1485072-B1 | HORMONE-CONTAINING TRANSDERMAL THERAPEUTIC SYSTEM WITH AN ACTIVE SUBSTANCE RESERVOIR BASED ON VINYLACETATE-VINYLPYRROLIDONE COPOLYMER WITH IMPROVED COHESION. | LOHMANN THERAPIE SYST LTS (DE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1485072-A1 | HORMONE-CONTAINING TRANSDERMAL THERAPEUTIC SYSTEM WITH AN ACTIVE SUBSTANCE RESERVOIR BASED ON VINYLACETATE-VINYLPYRROLIDONE COPOLYMER WITH IMPROVED COHESION. | LTS Lohmann Therapie-Systeme AG (DE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003077890-A1 | HORMONE-CONTAINING TRANSDERMAL THERAPEUTIC SYSTEM WITH AN ACTIVE SUBSTANCE RESERVOIR BASED ON VINYLACETATE-VINYLPYRROLIDONE COPOLYMER WITH IMPROVED COHESION. | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2003-09-25 | — | — | WO | disclosed |
| EP-1093361-B1 | PLASTER WHICH CONTAINS STEROIDS, AND A METHOD FOR THE PRODUCTION AND USE THEREOF | LOHMANN THERAPIE SYST LTS (DE) | 2003-05-02 | — | — | EP | disclosed |
| WO-2001089488-A1 | PLASTER CONTAINING ESTROGEN, WITH AN ACTIVE AGENT RESERVOIR BASED ON ETHYLCELLULOSE, POLYOXYETHYLENE LAURYL ALCOHOL AND AN ETHYLENE-VINYLACETATE-VINYLPYRROLIDONE COPOLYMER | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084398-A1 | SYSTEMS FOR MODULATING DRUG METABOLISM BY CELLS, METHODS AND COMPOSITIONS THEREOF | SHMT2, FPGS, GLS2 | MAPT 4362/4885KMT2A 1245/4885MEN1 3979/4885 |
| US-12448461-B2 | ABCB5 ligands and substrates | ABCB4, ABCD3, ABCB7 | MAPT 2673/4885KMT2A 4557/4885MEN1 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.